• Numerous network meta-analyses (NMAs) have evaluated disease-modifying drugs (DMDs) in relapsing-remitting multiple sclerosis (RRMS).
• The most frequent inclusion criteria for studies evaluated in the NMA were RRMS and randomized controlled trials (RCTs; Figure 1 ). Several studies explicitly stated that only patients with RRMS could be included. In five of the 25 studies, the patient population would be considered if .80% of patients had RRMS; in one study, the patient population would be considered if .50% had RRMS. Other commonly included inclusion criteria were:
-Duration of RCT follow-up (2 studies [1 study >12 months; 1 study >6 months])
-Reporting data to calculate odds ratios for treatment outcomes, including patients free of relapse, patients without disease progression, patients without magnetic resonance imaging (MRI) progression, and patients with adverse events (AEs; 2 studies) -Patient profile at baseline (1 study; detailed characteristics not reported).
• Studies evaluated in the pragmatic literature review generally examined more than one clinical endpoint: 80% of studies examined .1 clinical endpoint, 48% of studies examined .2, and 24% of studies examined .3. The most commonly reported endpoints were proportion of patients with disability progression (per Expanded Disability Status Scale [EDSS]), annualized relapse rate (ARR), and proportion of patients with AEs (Figure 2 ).
-Studies investigating AEs focused on several specific endpoints: proportion of patients with AEs/serious AEs and withdrawals due to AEs.
• (Figure 3 ).
-Novantrone ® (mitoxantrone; EMD Serono, Inc.*) and Nerventra ® (laquinimod; Teva Neuroscience Inc.) were studied twice in different NMAs; comparators studied in only one identified study were IFN alpha, pegylated IFN b-1a (pegIFN b-1a), methotrexate, cyclophosphamide, azathioprine, immunoglobulins, corticosteroids, levamisole, bovine myelin, rituximab, cladribine, ibudilast, fumarate, and ustekinumab.
• The most common analysis framework was Frequentist (employed in 40% of studies), compared with Bayesian analysis (employed in just 28% of studies; Figure 4A ). The analysis framework was not reported in the remaining studies.
-In Frequentist statistics, prior information is utilized formally only in the design of a clinical trial but not in the data analysis. In contrast, Bayesian statistics provide a means of combining prior information with current information at the design stage, during the conduct of the trial, and at the analysis stage. The Bayesian approach can also be applied to post-marketing surveillance and in meta-analyses. The basic tenets of good trial design are the same for both approaches. † -Bayesian analysis has been increasingly employed since 2013, and was used in six of 11 recent appraisals in the current review. Although most studies did not report the effects assumption, of those that did, 29% used a random-effects approach ( Figure 4B ).
-Bayesian models allow for ranking of treatment effects by surface under the cumulative ranking curve (SUCRA) analysis; the robustness of the model findings can be tested by comparing results against those obtained by the Frequentist approach.
• Most of the studies investigated (60%) did not report whether the impact of covariates was examined by use of meta-regression ( Figure 5 ). Furthermore, there was wide variability across sources in rates of reporting examination of covariates by metaregression, with the highest rate of reporting in HTA submissions (60%), followed by publications (33.3%) and poster abstracts (16.6%). Of the 40% of studies reporting metaregression, only 70% reported the precise covariates/subgroups examined.
-When reported, common covariates/subgroups included age, sex, year of publication, baseline EDSS score, and disease duration; others were number of relapses in previous year(s), baseline lesion volume, baseline number of gadolinium-enhancing lesions, and diagnostic criteria.
-In meta-regression, baseline disease characteristics and publication year had a significant impact on the results; significant covariates were baseline EDSS score (1 study), number of relapses in prior years (1 study), and year of publication (2 studies). Differences in outcomes by year of publication are likely to have been driven by changes in diagnostic criteria over time.
• Consistency tests were not often reported ( Figure 6) ; this was similar across HTA appraisals, poster abstracts, and publications (20.0%, 16.6%, and 11.1%, respectively). When reported, consistency tests were most often the Bucher test (2 of 4 studies), and comparison of results from direct, pairwise analyses versus indirect analyses (3 of 4 studies); one study used both approaches.
-The Bucher method is a simple z-test comparison that allows statistical evaluation of consistency. ‡
• Most studies did not report sensitivity analyses (Figure 7) . HTA appraisals were nearly twice as likely to report sensitivity analyses as other document types (HTA appraisals, 40%; publications, 22.2%; posters, 16.6%).
• Reported sensitivity analyses evaluated variations in study design or population, compared random-effects versus fixed-effects efficacy distributions, assessed the impact of choosing different prior distributions, and used models with stratification of treatment network by dosing versus without stratification. 
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• A pragmatic literature review was conducted to identify NMAs recently performed in RRMS. Based on our critical appraisal, we have identified best practices for NMAs in RRMS, including considerations for endpoints, analytical approaches, potential subgroup and meta-regression analyses, and tests for consistency and sensitivity.
• Endpoints that are most relevant to patients with RRMS (eg, proportion of patients relapse-free, proportion of patients with disease progression) should be explored in any efficacy-focused analysis.
-These endpoints should be investigated at a 2-year or longer follow-up duration, if possible, given the slow progression of RRMS.
• Bayesian analysis frameworks have emerged as more common in recent NMAs; however, as methodology for Frequentist analysis has recently improved, both methodologies are suitable for NMAs. The selection of the base case analysis approach should be driven by the desired model outputs; studies that aim to rank therapies should use Bayesian approaches to utilize SUCRA.
-Any analysis should aim to compare findings with those produced by a Frequentist framework as a sensitivity analysis to evaluate the robustness of findings.
• While similar endpoints are frequently compared across studies (eg, patients free of relapse, patients free from disability progression), the criteria for classifying these endpoints can vary. In addition, differences in patient demographics (eg, age, sex, previous treatment experience, and percentage of patients with RRMS) are likely to make an impact on the treatment effects observed in any given trial. Therefore, models that use a random-effects approach are likely to have greater face validity than those using a fixed-effects model, as the random-effects model better reflects the likely heterogeneity of treatment effects across studies.
-However, varying the effects distribution (fixed vs random effects) should be included as a sensitivity analysis in each model, as frequently observed in this appraisal. The comparison of findings across approaches can best support the robustness of results.
• Meta-regression analyses are likely to be useful within the RRMS space, as study-level differences (such as the diagnostic criteria employed, the year of patient enrollment in a study, etc) may lead to significant differences in results observed across trials.
• Although inconsistency tests were not frequently reported, these should be included in order to support the validity of results. Tests for consistency most commonly employed with RRMS include pairwise versus indirect comparisons and comparison of model fit using an inconsistency model.
• Possible limitations of the current analysis include the following:
-The pragmatic search strategy was limited in the time horizon investigated (2000 onwards for PubMed and Cochrane, and 2010 onwards for poster abstracts) and HTA decisions searched (as older therapies were not included); therefore, the findings here are likely not to represent an exhaustive list of all NMAs performed within the RRMS space, which may bias outcomes.
-HTA decisions and poster abstracts frequently do not report all the details related to the methodology employed within their analyses; therefore, these results may not properly reflect all the methods likely to have been employed for NMAs within RRMS.
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